TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07893054: A Phase I/Ib, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3219 Monotherapy or BNT3219 in Combination With Other I

Sponsor: BioNTech SE · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 207 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07893054 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07893054 Rescue Dossier →